Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Critical missing data on erythropoiesis-stimulating agents in CKD: first beat placebo.

Pfeffer MA.

Am J Kidney Dis. 2008 Mar;51(3):366-9. doi: 10.1053/j.ajkd.2008.01.003. No abstract available.

PMID:
18295051
2.

Cardiovascular disease and CKD: core curriculum 2010.

Shastri S, Sarnak MJ.

Am J Kidney Dis. 2010 Aug;56(2):399-417. doi: 10.1053/j.ajkd.2010.03.019. No abstract available.

PMID:
20599309
3.

[Statins: what is their place in the treatment of chronic kidney insufficiency?].

Ponte B, Bourquin V, Stoermann-Chopard C.

Rev Med Suisse. 2009 Feb 25;5(192):463-4, 466-8. French.

PMID:
19317313
4.

Anaemia: The safety and efficacy of peginesatide in patients with CKD.

Eckardt KU.

Nat Rev Nephrol. 2013 Apr;9(4):192-3. doi: 10.1038/nrneph.2013.42. Epub 2013 Mar 12. No abstract available.

PMID:
23478418
5.

Peginesatide as a new approach for treating anemia of CKD patient: is it like a falling star?

Locatelli F, Del Vecchio L.

Expert Opin Pharmacother. 2013 Jul;14(10):1277-80. doi: 10.1517/14656566.2013.799139. Epub 2013 May 16.

PMID:
23675762
6.

HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.

Romayne Kurukulasuriya L, Athappan G, Saab G, Whaley Connell A, Sowers JR.

Ther Adv Cardiovasc Dis. 2007 Oct;1(1):49-59. doi: 10.1177/1753944707082714. Review.

PMID:
19124395
7.

Erythropoiesis-stimulating agents on trial: are higher dosages causing harm?

Chaknos CM, Berns JS.

Am J Kidney Dis. 2013 Jan;61(1):6-8. doi: 10.1053/j.ajkd.2012.10.004. No abstract available.

PMID:
23245737
8.

Is there added value to adding ARB to ACE inhibitors in the management of CKD?

Cohen DL, Townsend RR.

J Am Soc Nephrol. 2009 Aug;20(8):1666-8. doi: 10.1681/ASN.2008040381. Epub 2008 Sep 5.

9.

Cardio-renal syndrome type 4: epidemiology, pathophysiology and treatment.

House AA.

Semin Nephrol. 2012 Jan;32(1):40-8. doi: 10.1016/j.semnephrol.2011.11.006. Review.

PMID:
22365161
10.

Quality of life in CKD patients treated with erythropoiesis-stimulating agents.

Parfrey PS, Wish T.

Am J Kidney Dis. 2010 Mar;55(3):423-5. doi: 10.1053/j.ajkd.2009.12.014. No abstract available.

PMID:
20189050
11.

Triumph and tragedy: anemia management in chronic kidney disease.

Novak JE, Szczech LA.

Curr Opin Nephrol Hypertens. 2008 Nov;17(6):580-8. doi: 10.1097/MNH.0b013e32830c488d. Review.

PMID:
18941350
12.

[Chronic renal insufficiency and cardiovascular disease].

Charriere S, Rognant N, Chiche F, Cremer A, Deray G, Priou M.

Ann Cardiol Angeiol (Paris). 2009 Feb;58(1):40-52. doi: 10.1016/j.ancard.2008.07.010. Epub 2008 Aug 19. Review. French.

PMID:
18937921
13.

Treatment of nephrotic syndrome: retrospection.

Yee J.

Adv Chronic Kidney Dis. 2014 Mar;21(2):115-8. doi: 10.1053/j.ackd.2014.01.012. No abstract available.

PMID:
24602460
14.
15.

Are consistency and individualization mutually exclusive in erythropoiesis-stimulating agent therapy?

Wish JB.

Am J Kidney Dis. 2012 Sep;60(3):340-2. doi: 10.1053/j.ajkd.2012.06.007. No abstract available.

PMID:
22901630
16.

Anemia and cardiovascular risk in the patient with kidney disease.

Fishbane S.

Heart Fail Clin. 2008 Oct;4(4):401-10. doi: 10.1016/j.hfc.2008.03.005. Review.

PMID:
18760752
17.
18.

[Use of erythropoiesis stimulating agents].

Abreu PF, Romão Junior JE, Bastos MG.

J Bras Nefrol. 2014 Mar;36(1 Suppl 1):19-23. Portuguese. No abstract available.

19.

Benazepril for advanced chronic renal insufficiency.

Bloom JM.

N Engl J Med. 2006 Apr 6;354(14):1530-1; author reply 1530-1. No abstract available.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk